Tivic Health (Nasdaq:TIVC) announced today that its funded study for vagus nerve stimulation received Institutional Review Board (IRB) approval.
San Francisco-based Tivic Health’s study takes place at the Feinstein Institutes for Medical Research. With IRB approval, the company can begin recruitment and enrollment for the study of its non-invasive bioelectronic nerve stimulation device. In collaboration with Tivic Health, the Feinstein Institutes initiated recruitment and completed the first patient enrollment. The study
An IRB, an FDA-registered group, reviews and monitors biomedical research involving human subjects. It can approve, require modifications to or disapprove research. An IRB serves an important role in protecting the rights and welfare of human research subjects, Tivic said in a news release.
The study utilizes a new neurostimulation approach with 20 individuals, plus data analysis and algorithm development. It may provide greater ta…